Glenmark Life Sciences Ltd - 543322 - Reg. 34 (1) Annual Report.
Submission of Annual Report under Regulation 34 (1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201530-08-2022
30-08-2022
Glenmark Life Sciences Ltd - 543322 - Notice Of 11Th Annual General Meeting Of The Company For FY 2021-22
Further to our letter dated August 23, 2022 and pursuant to Regulation 30 of the Listing Regulations, enclosed please find herewith the Notice and Explanatory statement Convening the 11th Annual General Meeting (AGM) scheduled to be held on Monday, September 26, 2022 at 2.00 p.m. IST through Video Conferencing (VC) / Other Audio-Visual Means (OAVM). The notice of AGM is being sent to all the members whose email Ids have been registered with the Company. The Company is pleased to provide to its members the facility to exercise their right to vote on the resolutions proposed to be passed at the AGM by electronic means. Only Shareholders, whose name is recorded in the register of members or in the register of beneficial owners maintained by the depositories as on the cut-off date, i.e. Monday, September 19, 2022, shall be entitled to avail thee-voting facility.30-08-2022
Glenmark Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, enclosed are the copies of newspaper advertisement informing the Members about the 11th Annual General Meeting scheduled to be held on Monday, September 26, 2022 at 2:00 p.m. IST through Video Conferencing (VC) / Other Audio Visual Means (OAVM), as published in Financial Express (English) all India edition and Loksatta (Marathi) today i.e. on August 27, 2022.27-08-2022
Glenmark Life Sciences Ltd - 543322 - Intimation Of The Date Of 11Th Annual General Meeting And Book Closure Pursuant To Regulation 42 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
We have to inform you that the 11th Annual General Meeting (AGM) of Members of the Company is scheduled to be held on Monday, September 26, 2022 at 2.00 p.m. through Video Conferencing ("VC") / Other Audio Visual Means (''OAVM"). The copy of the notice will be sent to you in due course. Pursuant to the Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Register of Members and the Share Transfer Books of the Company will remain closed from Saturday, September 17, 2022 to Monday, September 26, 2022 (both days inclusive) for the purpose of the AGM and determining the names of the eligible Members for equity dividend.23-08-2022
Glenmark Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Monitoring Agency Report
Pursuant to Regulation 32(6) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 read with Regulation 41(4) of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, we are enclosing herewith Monitoring Agency Report issued by HDFC Bank Limited, Monitoring Agency, for the quarter ended 30th June, 2022 in respect of utilization of proceeds of the IPO of the Company.12-08-2022
Glenmark Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Pursuant to Regulation 30(6) read with Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, the transcript of the Earnings call held on Friday, 5th August, 2022 for the quarter ended June 30, 2022 is available on the Company's website at: https://www.glenmarklifesciences.com/pdf/Transcript%20of%20Earnings%20Concall%20Q1%20FY2022-23.pdf Request you to kindly take the same on record.08-08-2022
Glenmark Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Audio recording of Q1 FY2022-23 Earnings Call Pursuant to the Regulation 30 and 46 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we hereby confirm that we have uploaded audio recording of the Q1 FY2022-23 Earnings Call held on 5th August, 2022 on the website of the Company at: https://www.glenmarklifesciences.com/pdf/GLE9320220805142632.mp305-08-2022
Glenmark Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Investor Presentation
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing the investor presentation.04-08-2022
Q1FY23 Quarterly Result Announced for Glenmark Life Sciences Ltd.
Glenmark Life Sciences announced Q1FY23 results: GLS registered revenue from operations of Rs 4,898.7 million for Q1 FY23, recording a YoY decline of 6.7% due to high base of COVID products sales last year. (+6.5% YoY excluding COVID products) Gross margins for the quarter improved to 53.3% mainly driven by booking of PLI scheme incentive. Gross Margins excluding PLI scheme incentive were stable at 52.0 % driven by better product mix and cost optimization efforts. Earnings Before Interest, Tax, Depreciation and Amortization (EBITDA) was at Rs 1,562.6 million for Q1 FY23 with margin at 31.9%. Profit After Tax (PAT) was at Rs 1,087.3 million in Q1 FY23, registering a growth of 7.7% YoY Commenting on the company’s performance, Dr. Yasir Rawjee, MD & CEO, Glenmark Life Sciences Limited said, “We are pleased with our performance in this quarter with the overall business growing steadily, ex-covid products. India, LATAM, and ROW continue to lead our growth with Europe being soft due to supply chain issues. Generic API business saw a healthy growth of 7.1% YoY ex-covid products, whereas CDMO business witnessed an impact due to inventory rationalisation at customers’ end. We are witnessing improvement in demand for APIs across geographies, and I am optimistic about continuing the growth momentum in coming quarters” Dr. Rawjee further added, “Our CAPEX plans are slightly delayed but we expect closure on some of these investments by the end of Q2 FY23. Our brownfield projects continue to be on track and will be completed by the end of this fiscal year. The addition of these new capacities will facilitate sustainable growth as we expand our product portfolio and continue to deliver higher volumes for existing products in the coming years.” Result PDF04-08-2022
Glenmark Life Sciences Ltd - 543322 - Unaudited Financial Results For The First Quarter Ended June 30, 2022
Pursuant to Regulations 30 and 33 of the SEBI LODR, 2015, we wish to inform you that the Board at its meeting held today approved the Unaudited Financial Results for the First Quarter ended June 30, 2022. The said meeting of the Board commenced at 3.30 p.m. and concluded at 6.05 p.m. The copy of the said results together with Management Discussion & Analysis, Press Release and Limited Review Report of the Auditors is enclosed herewith. These are also being made available on the website of the Company at www.glenmarklifesciences.com04-08-2022